Securities Fraud Class Action Filed Against PROCEPT BioRobotics Over Alleged Discount Program
PRCT is trading near its 52-week low of $16.665 (11% above the low) on elevated volume (1.8× avg).
Summary
A securities fraud class action lawsuit has been filed against PROCEPT BioRobotics and certain senior executives, alleging the company artificially inflated financial performance through a discount program that encouraged bulk handpiece orders exceeding actual procedures. The suit claims this led to inflated sales figures and subsequent stock drops of 16%, 10%, and 18% on earnings releases in August 2025, November 2025, and February 2026. This follows the February 2026 guidance cut and 30% U.S. handpiece volume decline reported yesterday, adding legal risk to the operational challenges. The lawsuit is in early stages with a lead plaintiff deadline of September 22, 2026, and could result in significant financial penalties and management distraction if certified.
At the time of this announcement, PRCT was trading at $18.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $16.67 to $51.18. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.